Login Register Cart 0
Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Quinoline-3-Carboxylic Acids “DNA Minor Groove-Binding Agent”

Author(s): Priyank Purohit*, Ravi K. Mittal and Kavita Khatana

Volume 22, Issue 2, 2022

Published on: 11 August, 2021

Page: [344 - 348] Pages: 5

DOI: 10.2174/1871520621666210513160714

Price: $65

Abstract

Background: The lead compounds from the series of 2, 4-disubstituted quinoline-3-carboxylic acid derivatives were selected for the in-silico mechanistic study. The compounds were found selective and potent for the cancer cell. Moreover, the relevant ADME in-silico data also support the safety of lead.

Objective: The objective of the study is to correlate the interaction of DNA and quinoline derivative, which was reported with the fluorescence microscopy images of cells in-vitro data in the recently published data.

Methods: The detailed interaction study with the DNA dodecanucleotide sequenced d(CGCGAATTCGCG) shows the present lead bounds with the A/T minor groove region of a B-DNA duplex through the important major and minor hydrogen bonds.

Results: The present in-silico study supports the interactions of the drug with DNA with sufficient binding interactions and energy. The present study also gives vital information related to the mechanism of drug action, which was initially declared as a DNA targeting molecule through a fluorescence-based target study.

Conclusion: The substitution at 2nd position (the carbonyl group) of the lead revealed as a hydrogen bond donor/acceptor for adenine and guanine nucleic acid-base pair. The in-silico prediction also confirmed the interaction pattern of the lead with the DNA, which will be further utilized for drug development.

Keywords: DNA interaction, minor groove binding agent, anti-cancer drug, quinoline, in silico interaction, heterocyclic moiety.

« Previous Next »
Graphical Abstract

[1]
Narasimhan, B.; Sharma, D.; Kumar, P. Benzimidazole: a medicinally important heterocyclic moiety. Med. Chem. Res., 2012, 21(3), 269-283.
[http://dx.doi.org/10.1007/s00044-010-9533-9]
[2]
Sperry, Jeffrey B.; Wright, Dennis L. Furans, thiophenes and related heterocycles in drug discovery. Current Opin.ion in Drug Discovery and Development,, 2005, 8(6), 723.
[3]
Seth, K.; Purohit, P.; Chakraborti, A.K. Microwave assisted synthesis of biorelevant benzazoles. Curr. Med. Chem., 2017, 24(41), 4638-4676.
[PMID: 27781941]
[4]
Jadhavar, P.S.; Kumar, D.; Purohit, P.; Pipaliya, B. V. Sustainable approaches towards the synthesis of quinoxalines.Green Chemistry: Synthesis of Bioactive Heterocycles, 2014, 37-67.,
[5]
Jain, S.; Chandra, V.; Jain, P.K.; Pathak, K.; Pathak, D.; Vaidya, A. Comprehensive review on current developments of quinoline-based anticancer agents. Arab. J. Chem., 2019, 12(8), 4920-4946.
[http://dx.doi.org/10.1016/j.arabjc.2016.10.009]
[6]
Weyesa, A.; Mulugeta, E. Recent advances in the synthesis of biologically and pharmaceutically active quinoline and its analogues: a review. RSC Advances, 2020, 10(35), 20784-20793.
[http://dx.doi.org/10.1039/D0RA03763J]
[7]
Mittal, R.K.; Purohit, P. Quinoline-3-carboxylate derivatives: A new hope as an antiproliferative agent. Anticancer. Agents Med. Chem., 2020, 20(16), 1981-1991.
[http://dx.doi.org/10.2174/1871520620666200619175906] [PMID: 32560612]
[8]
Mittal, R.K.; Purohit, P. Quinoline-3-carboxylic acids: A step toward highly selective antiproliferative agent.Anticancer. Agents Med. Chem., 2020, Online ahead of print.,
[http://dx.doi.org/10.2174/1871520620999201124214112] [PMID: 33238852]
[9]
Kalanur, S.S.; Katrahalli, U.; Seetharamappa, J. Electrochemical studies and spectroscopic investigations on the interaction of an anticancer drug with DNA and their analytical applications. J. Electroanal. Chem., 2009, 636(1-2), 93-100.
[http://dx.doi.org/10.1016/j.jelechem.2009.09.018]
[10]
Krugh, T.R. Drug-DNA interactions. Curr. Opin. Struct. Biol., 1994, 4(3), 351-364.
[http://dx.doi.org/10.1016/S0959-440X(94)90103-1]
[11]
Chaires, J.B. Drug--DNA interactions. Curr. Opin. Struct. Biol., 1998, 8(3), 314-320.
[http://dx.doi.org/10.1016/S0959-440X(98)80064-X] [PMID: 9666327]
[12]
(a)Schrödinger Release 2017-3: Schrödinger Suite 2017-3 Protein Preparation Wizard;.
(b)Epik, Schrödinger; LLC: New York, NY, 2017..
(c)Impact Schrödinger; LLC: New York, NY, 2017..
(d)LigPrep Schrödinger; LLC: New York, NY, 2017..
(e)Prime Schrödinger; LLC: New York, NY, 2017..
(f)QikProp Schrödinger; LLC: New York, NY,. , 2017.
[13]
Harder, E.; Damm, W.; Maple, J.; Wu, C.; Reboul, M.; Xiang, J.Y.; Wang, L.; Lupyan, D.; Dahlgren, M.K.; Knight, J.L.; Kaus, J.W.; Cerutti, D.S.; Krilov, G.; Jorgensen, W.L.; Abel, R.; Friesner, R.A. OPLS3: A force field providing broad coverage of drug-like small molecules and proteins. J. Chem. Theory Comput., 2016, 12(1), 281-296.
[http://dx.doi.org/10.1021/acs.jctc.5b00864] [PMID: 26584231]
[14]
Sastry, G.M.; Adzhigirey, M.; Day, T.; Annabhimoju, R.; Sherman, W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J. Comput. Aided Mol. Des., 2013, 27(3), 221-234.
[http://dx.doi.org/10.1007/s10822-013-9644-8] [PMID: 23579614]
[15]
Friesner, R.A.; Banks, J.L.; Murphy, R.B.; Halgren, T.A.; Klicic, J.J.; Mainz, D.T.; Repasky, M.P.; Knoll, E.H.; Shelley, M.; Perry, J.K.; Shaw, D.E.; Francis, P.; Shenkin, P.S. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem., 2004, 47(7), 1739-1749.
[http://dx.doi.org/10.1021/jm0306430] [PMID: 15027865]
[16]
Bashford, D.; Case, D.A. Generalized born models of macromolecular solvation effects. Annu. Rev. Phys. Chem., 2000, 51, 129-152.
[http://dx.doi.org/10.1146/annurev.physchem.51.1.129] [PMID: 11031278]
[17]
Mann, J.; Baron, A.; Opoku-Boahen, Y.; Johansson, E.; Parkinson, G.; Kelland, L.R.; Neidle, S. A new class of symmetric bisbenzimidazole-based DNA minor groove-binding agents showing antitumor activity. J. Med. Chem., 2001, 44(2), 138-144.
[http://dx.doi.org/10.1021/jm000297b] [PMID: 11170623]
[18]
Lauria, A.; Montalbano, A.; Barraja, P.; Dattolo, G.; Almerico, A.M. DNA minor groove binders: an overview on molecular modeling and QSAR approaches. Curr. Med. Chem., 2007, 14(20), 2136-2160.
[http://dx.doi.org/10.2174/092986707781389673] [PMID: 17691953]
[19]
Spink, N.; Brown, D.G.; Skelly, J.V.; Neidle, S. Sequence-dependent effects in drug-DNA interaction: the crystal structure of Hoechst 33258 bound to the d(CGCAAATTTGCG)2 duplex. Nucleic Acids Res., 1994, 22(9), 1607-1612.
[http://dx.doi.org/10.1093/nar/22.9.1607] [PMID: 7515488]

Rights & Permissions Print Cite
Article Metrics
29
3
© 2024 Bentham Science Publishers | Privacy Policy